Humacyte (NASDAQ:HUMA) Issues Earnings Results, Misses Estimates By $0.06 EPS

Humacyte (NASDAQ:HUMA) posted its earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.06), FiscalAI reports. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. The business had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.12 million.

Here are the key takeaways from Humacyte’s conference call:

• V012 Phase III interim results exceeded expectations in female dialysis patients: ATEV recipients had 91 more catheter-free days than AV fistula patients, with significantly fewer infections. Humacyte plans to file a supplemental BLA in November 2026 and is targeting a potential launch in late Q2 2027 if priority review is granted.
• Humacyte is rebuilding its SYMVESS commercial organization with vascular-surgery-focused sales personnel, a national accounts strategy, streamlined hospital value-analysis processes, and introductory pricing. At least 20 major U.S. healthcare systems are reportedly in the process of adopting the product, although meaningful benefits are expected mainly in the second half of 2026.
• The FDA accepted Humacyte’s IND for its smaller-diameter CTEV vessel in coronary artery bypass grafting, and the company expects to begin a 10-patient Phase IIa study during the current quarter. Management said initial CTEV manufacturing will not materially constrain ATEV commercial production.
• Financial results continued to reflect commercialization and manufacturing costs: second-quarter revenue was only $0.4 million, cost of goods sold reached $1.2 million including a $0.7 million inventory reserve, and net loss was $36.8 million. Cash, cash equivalents, and restricted cash totaled $80.3 million at June 30, 2026, supported in part by equity-sale proceeds.

Humacyte Trading Down 11.3%

Shares of HUMA stock traded down $0.08 during trading hours on Wednesday, reaching $0.63. 6,773,800 shares of the stock traded hands, compared to its average volume of 7,854,669. Humacyte has a 1-year low of $0.55 and a 1-year high of $2.55. The business has a fifty day moving average price of $0.82 and a 200 day moving average price of $0.91. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. The firm has a market capitalization of $139.89 million, a PE ratio of -1.11 and a beta of 2.53.

Insider Buying and Selling

In other Humacyte news, CFO Dale A. Sander sold 45,887 shares of Humacyte stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the transaction, the chief financial officer directly owned 267,213 shares in the company, valued at approximately $240,491.70. The trade was a 14.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius bought 56,818 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were purchased at an average cost of $0.88 per share, for a total transaction of $49,999.84. Following the completion of the purchase, the director owned 148,025 shares in the company, valued at approximately $130,262. This trade represents a 62.30% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Humacyte by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 7,520,055 shares of the company’s stock valued at $13,085,000 after purchasing an additional 520,431 shares during the period. Geode Capital Management LLC grew its position in Humacyte by 20.2% during the fourth quarter. Geode Capital Management LLC now owns 3,720,436 shares of the company’s stock valued at $3,574,000 after purchasing an additional 624,220 shares in the last quarter. State Street Corp increased its stake in Humacyte by 17.8% in the 4th quarter. State Street Corp now owns 2,837,276 shares of the company’s stock valued at $2,725,000 after buying an additional 429,233 shares during the period. Marshall Wace LLP increased its stake in Humacyte by 5,308.2% in the 2nd quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock valued at $5,516,000 after buying an additional 2,590,394 shares during the period. Finally, Millennium Management LLC lifted its position in Humacyte by 129.5% in the 4th quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock worth $2,528,000 after buying an additional 1,485,152 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on HUMA shares. HC Wainwright increased their price objective on shares of Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a report on Thursday, June 11th. TD Cowen lowered their price target on Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a research report on Wednesday, June 17th. Wall Street Zen upgraded Humacyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Humacyte in a report on Tuesday, April 28th. Finally, BTIG Research restated a “buy” rating and set a $2.00 price objective on shares of Humacyte in a research report on Wednesday. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.25.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.